ArticleAnnals of medicine2025
Impact of diabetes and glycemic control during cancer care on mortality in non-metastatic solid and hematologic malignancies.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis.Biomolecules · 2025Pooled it
- Diabetes and cancer: glucose control impact on survival and tumor outcomes.Reviews in endocrine & metabolic disorders · 2026Review
- Type 2 diabetes and cancer: A retrospective longitudinal comparative cohort study of disease sequence and comorbidity profiles.PloS one · 2026Article
- Decoding the tumor-aging axis: from bench to clinical.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether cancer patients with diabetes can achieve survival outcomes comparable to those without diabetes through appropriate glycemic control over the course of cancer remains uncertain.
aimTo assess mortality risk among cancer patients with diabetes compared to those without diabetes, and to evaluate whether this risk differed by level and pattern of visit-to-visit glycemic control. MATERIALS AND
methodsWe conducted a retrospective cohort study using electronic health records from a tertiary cancer center. Adults with non-metastatic solid or hematologic malignancies and a history of diabetes, treated between 2009 and 2021, were individually matched in a 1:2 ratio to cancer patients without diabetes based on cancer type, sex, age, and treatment year, and were followed through June 2024. Mortality risks were assessed, accounting for cancer stage, aggressiveness, comorbidities, BMI, and cancer and diabetes treatments.
resultsAmong 29,812 patients, 1948 (650 with diabetes and 1298 without) were eligible, with a total follow-up of 112,809 patient-months. Mortality risk among patients with diabetes was similar to those without (adjusted HR, 1.11 [0.89-1.39];
conclusionsOverall, the mortality risk among patients with cancer and diabetes was comparable to those without diabetes. However, among those with diabetes, poor glycemic control, hypoglycemia, and high glycemic variability were associated with worse survival-highlighting the need for integrated, chronic disease-informed cancer care strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.